// App-Quantinova.ai

3410 : Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Researchers

Presenter

  • Jeffery J Auletta

Principal Investigators

  • Sumithira Vasu

  • Rolla Abu-Arja

  • Hemalatha G. Rangarajan

  • Rajinder Bajwa

  • Edwin M Horwitz

  • Lynn -Donnell

  • Samantha Jaglowski

  • Rebecca B Klisovic

  • Sam Penza

  • Yvonne A Efebera

  • Craig C Hofmeister

  • Ying Huang

  • Ashley E Rosko

  • Don M Benson

  • Leslie A. Andritsos

  • William Blum

  • Steven M Devine

  • Qiuhong Zhao

  • Amy S. Ruppert

  • Abigail Shoben

  • Patrick Elder

  • Anissa Bingman

  • Rhonda Kitzler

  • Gerard Lozanski

Medical Centers

  • The James Comprehensive Cancer Center, Ohio State University, Columbus, OH

  • Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Division of Biostatistics, The Ohio State University College of Public Health, Columbus, OH

  • Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH

  • The Ohio State Univerisity, Columbus, OH

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Department of Infectious Diseases, Nationwide Childrens Hospital, Columbus, OH

  • Department of Pathology, The Ohio State University, Columbus, OH

  • Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH

  • Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Invasive fungal infection

  • Myelodysplastic Syndrome

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved